Metagenomi (NASDAQ:MGX – Free Report) had its price target cut by BMO Capital Markets from $22.00 to $17.00 in a research report report published on Thursday, Benzinga reports. They currently have an outperform rating on the stock.
Several other equities analysts have also commented on the company. JPMorgan Chase & Co. lowered Metagenomi from an overweight rating to a neutral rating and decreased their price target for the company from $16.00 to $6.00 in a research note on Thursday, May 2nd. HC Wainwright reissued a buy rating and issued a $10.00 price target on shares of Metagenomi in a research note on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $17.00.
Check Out Our Latest Stock Report on Metagenomi
Metagenomi Price Performance
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in Metagenomi during the 2nd quarter worth about $66,000. Resolute Advisors LLC grew its position in shares of Metagenomi by 165.0% during the second quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock worth $108,000 after buying an additional 16,500 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Metagenomi during the second quarter worth approximately $26,000. Farallon Capital Management LLC acquired a new stake in Metagenomi in the first quarter valued at approximately $14,171,000. Finally, RA Capital Management L.P. acquired a new stake in Metagenomi in the first quarter valued at approximately $18,404,000.
Metagenomi Company Profile
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Read More
- Five stocks we like better than Metagenomi
- How to Capture the Benefits of Dividend Increases
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Consumer Staples Stocks, Explained
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.